Loading data for EBS — first visit, this takes a few seconds.
Emergent BioSolutions Inc... (EBS)
NYSE: EBS
· Real-Time Price · USD
4.59
+0.10 (2.23%)
At close: Aug 14, 2026, 8:00 PM
4.57
-0.44%
After-hours: 7:34 PM
Emergent BioSolutions Inc. (EBS) Stock Price, Analysis & Data
2.23% (1D)
No data available
| Bid | n/a |
| Market Cap | 235.34M |
| Revenue (ttm) | 770.2M |
| Net Income (ttm) | -176.8M |
| Beta | 2.36 |
| EPS (ttm) | -3.41 |
| PE Ratio (ttm) | n/a |
| Forward PE | 1.54 |
| P/B (ttm) | 0.69 |
| P/S (ttm) | 0.31 |
| Earnings Date | Oct 28, 2026 |
| Ask | n/a |
| Volume | 1,094,300 |
| Avg. Volume (20D) | 1,015,148 |
| Open | 4.50 |
| Previous Close | 4.49 |
| Day's Range | 4.45 - 4.67 |
| 52-Week Range | 4.36 - 14.06 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeuti...
Full Company ProfileFinancial Performance
In 2025, Emergent BioSolutions's revenue was 705.2M, a decrease of -30.43% compared to the previous year's 1.01B. Earnings were 52.6M, a decrease of -127.6%.
Financial StatementsEarnings Surprise
Emergent BioSolutions has released their quarterly earnings on Aug 5, 2026:
Emergent BioSolutions Inc. is scheduled to release its earnings on Oct 28, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2